Milestone Pharmaceuticals Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Milestone Pharmaceuticals Inc. (MIST) reported Revenue from Contract with Customer, Excluding Assessed Tax of $559.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $559.00K.
- Milestone Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $238.00K.
- Milestone Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00.
- Milestone Pharmaceuticals Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month |
|---|---|---|
| 2026-06-30 | $559.00K 10-Q · filed 2026-08-12 | $797.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $238.00K 10-Q · filed 2026-05-13 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |